Characterization of OX40+ T cells detected in patients with GVHD after hematopoietic stem cell transplantation

造血干细胞移植后 GVHD 患者中检测到的 OX40 T 细胞的特征

基本信息

  • 批准号:
    13670454
  • 负责人:
  • 金额:
    $ 2.3万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 财政年份:
    2001
  • 资助国家:
    日本
  • 起止时间:
    2001 至 2002
  • 项目状态:
    已结题

项目摘要

We studied the role of the OX40/OX40L in GVHD that is though to be ascribed to alloreactive immune response of donor-derive T cells to recipient cells.We examined the expression of OX40 on peripheral blood T cells of post-stem cell transplantation patients after day 100. The percentages of both OX40^+CD4^+ and OX40^+CD8^+ T cells were significantly higher in patients with chronic c GVHD than those without. Serial analyses showed that OX40^+CD4^+ T cells elevated before the onset of cGVHD and at the onset closely correlated with the therapeutic response. These results indicated that serial measurement of OX40^+ T cells is useful for predicting the onset as well as therapeutic response of cGVHD and raised a possibility that the OX40/gp34 system is involved in the pathogenesis of cGVHD (Blood 98:3162, 2001). To define the role of the OX40/OX40L system in alloreactivity in more detail, we examined the effect of anti-OX40L mAb on proliferative response of CD4^+ T cells to allogeneic monocyte-derived DCs. We observed that expression of OX40 was dependent on CD28 signals and anti-OX40L mAb markedly inhibited proliferative response of CD4^+ T cells to allogeneic DC and even to sorted OX40L^- DC, indicating that the OX40/OX40L system plays a crucial role in allogeneic T cell immune response (Immunology, 109:226-231, 2003). We found that OX40 signaling induces production of RANTES at both mRNA and protein levels by vascular endothelial cells, which we first identified in screening with cDNA array (Immunol. Lett. 84:1, 2002). Now that CCR5^+ T cells are considered to initiate GVHD (Nature Immunol. 4:154, 2003), this finding may be of pathophysiological relevance.
我们研究了OX 40/OX 40 L在GVHD中的作用,GVHD被认为是供体来源的T细胞对受体细胞的同种异体反应性免疫应答,我们检测了干细胞移植后100天患者外周血T细胞上OX 40的表达。慢性c型GVHD患者的OX 40 ^+ CD 4 ^+和OX 40 ^+ CD 8 ^+ T细胞百分比均显著高于无慢性c型GVHD患者。系列分析显示,OX 40 ^+ CD 4 ^+ T细胞在cGVHD发病前和发病时升高,与治疗反应密切相关。这些结果表明,连续测量OX 40 ^+ T细胞可用于预测cGVHD的发作以及治疗反应,并提出了OX 40/gp 34系统参与cGVHD发病机制的可能性(Blood 98:3162,2001)。为了更详细地确定OX 40/OX 40 L系统在同种异体反应性中的作用,我们检测了抗OX 40 L mAb对CD 4 ^+ T细胞对同种异体单核细胞来源的DC的增殖反应的影响。我们观察到OX 40的表达依赖于CD 28信号,抗OX 40 L mAb显著抑制了CD 4 ^+ T细胞对同种异体DC甚至分选的OX 40 L ^- DC的增殖反应,表明OX 40/OX 40 L系统在同种异体T细胞免疫应答中起着至关重要的作用(Immunology,109:226-231,2003)。我们发现,OX 40信号传导诱导血管内皮细胞在mRNA和蛋白质水平上产生RANTES,这是我们在用cDNA阵列筛选时首次鉴定的(Immunol. Lett. 84:1,2002)。既然CCR 5 ^+ T细胞被认为是GVHD的启动细胞(Nature Immunol.4:154,2003),这一发现可能与病理生理学有关。

项目成果

期刊论文数量(17)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Ai Kotani, et al.: "Correlation of peripheral blood OX40^+ (CD134^+) T cells with chronic graft-versus-host disease in patients who underwent allogeneic hematopoietic stem cell transplantation"Blood. 98. 3162-3164 (2001)
Ai Kotani 等人:“接受同种异体造血干细胞移植的患者外周血 OX40^ (CD134^) T 细胞与慢性移植物抗宿主病的相关性”血液。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Yumi Matsumura, et al.: "Expression of CD134 and CD134 ligand in lesional and nonlesional psoriatic skin"Arch. Dermatol. Res.. 294. 563-566 (2002)
Yumi Matsumura 等人:“CD134 和 CD134 配体在病变和非病变银屑病皮肤中的表达”Arch。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Ai Kotani, et al.: "Singnaling of gp34 (OX40 ligand) induces vascular endothelial cells to produce a CC chemokine RANTES/CCL5"Immunol. Lett.. 84. 1-7 (2002)
Ai Kotani 等人:“gp34(OX40 配体)的信号传导诱导血管内皮细胞产生 CC 趋化因子 RANTES/CCL5”Immunol。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Ai Kotani, Toshiyuki Hori, Yumi Matsumura, and Takashi Uchiyama: "Singnaling of gp34 (OX40 ligand) induces vascular endothelial cells to produce RANTES"Immunol. Let.. 84. 1-7 (2002)
Ai Kotani、Toshiyuki Hori、Yumi Matsumura 和 Takashi Uchiyama:“gp34(OX40 配体)的信号诱导血管内皮细胞产生 RANTES”Immunol。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

HORI Toshiyuki其他文献

HORI Toshiyuki的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('HORI Toshiyuki', 18)}}的其他基金

Search for RASSF-interacting molecules using C. elegans
使用线虫搜索 RASSF 相互作用分子
  • 批准号:
    23501272
  • 财政年份:
    2011
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Molecular pathogenesis of abnormal kpm (Lats2) expression in leukemia
白血病kpm(Lats2)表达异常的分子发病机制
  • 批准号:
    20591122
  • 财政年份:
    2008
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Involvement of guanylyl cyclase signals of dendritic cells in allergic state
过敏状态下树突状细胞鸟苷酸环化酶信号的参与
  • 批准号:
    17607006
  • 财政年份:
    2005
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Immunohematologic studies on the SDF-1/CXCR-4 system with monoclonal antibod.
使用单克隆抗体对 SDF-1/CXCR-4 系统进行免疫血液学研究。
  • 批准号:
    09671107
  • 财政年份:
    1997
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)

相似海外基金

Development of Induced pluripotent stem cell-derived macrophages expressing OX40 ligand therapy
表达 OX40 配体疗法的诱导多能干细胞衍生巨噬细胞的开发
  • 批准号:
    20K22850
  • 财政年份:
    2020
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Development of new refractory asthma treatments of targeting OX40 ligand.
开发针对 OX40 配体的新型难治性哮喘治疗方法。
  • 批准号:
    24790093
  • 财政年份:
    2012
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Trial to the therapeutic strategy for inflammatory disorders by targeting immunomodulatory molecule OX40 ligand
靶向免疫调节分子OX40配体治疗炎症性疾病策略的尝试
  • 批准号:
    21591289
  • 财政年份:
    2009
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Immune regulation by OX40/OX40 ligand system
OX40/OX40配体系统的免疫调节
  • 批准号:
    11670311
  • 财政年份:
    1999
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了